Drug Type Small molecule drug |
Synonyms Pitavastatin Calcium Hydrate/Ezetimibe, 依折麦布/匹伐他汀钙, AD-2284 + [6] |
Target |
Action inhibitors |
Mechanism CETP inhibitors(Cholesteryl ester transfer protein inhibitors), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date South Korea (28 Jul 2021), |
Regulation- |
Molecular FormulaC25H24CaFNO4 |
InChIKeyAMUDYCAFPCQTAZ-NRFPMOEYSA-N |
CAS Registry147526-32-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypercholesterolemia | Japan | 26 Sep 2022 | |
Hyperlipoproteinemia Type II | Japan | 26 Sep 2022 | |
Primary hypercholesterolemia | South Korea | 28 Jul 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Homozygous familial hypercholesterolemia | Phase 1 | China | 20 Sep 2022 |
Phase 3 | 109 | K-924 LD: 2 mg/10 mg | octyzthvyc(ivlihqcqzj) = neimhszrza mlqudgmwlz (xmbstevcyl ) | Positive | 01 Mar 2024 | ||
K-924 HD: 4 mg/10 mg | octyzthvyc(ivlihqcqzj) = esqmiqhzsd mlqudgmwlz (xmbstevcyl ) |